Servier

Servier is a privately held French pharmaceutical group headquartered in Suresnes, near Paris. Founded in 1954 by Jacques Servier, it developed from a French laboratory into an international research-based company with operations spanning drug discovery, clinical development, manufacturing and commercial distribution. Unlike a publicly traded pharmaceutical company, Servier has remained privately controlled and states that its ownership and governance are intended to preserve a long-term research mission. The company has historically built a broad prescription-medicine portfolio, with notable products in cardiovascular medicine, diabetes, venous disease, gastroenterology, psychiatry and oncology. Its international reputation was strengthened by medicines such as Coversyl, a perindopril-based cardiovascular treatment; Daflon, used for chronic venous disease and haemorrhoidal symptoms; Procoralan, based on ivabradine; and Valdoxan, an agomelatine antidepressant. Product availability, indications and brand ownership can vary by country, and several older products have faced generic competition or patent expiry. In the 2010s Servier progressively repositioned itself toward specialty pharmaceuticals, particularly oncology and immuno-inflammatory disease. The group expanded its oncology capabilities through internal research, licensing and acquisitions. Important examples include its partnership with Japan’s Taiho Pharmaceutical around Lonsurf, an oral treatment for advanced colorectal and gastric or gastroesophageal-junction cancers, and its acquisition of U.S. oncology company Symphogen in 2019. Servier also acquired oncology assets and commercial rights from other companies, including the U.S. rights to Onivyde from Merrimack Pharmaceuticals in 2017. In 2023 it completed the acquisition of Agios Pharmaceuticals’ oncology business, adding vorasidenib and other investigational or commercial assets to its portfolio. Servier’s research activities are organized around areas including oncology, immuno-inflammation, neuroscience and cardiovascular or metabolic disease. The company operates research and development sites and manufacturing facilities in multiple countries, and collaborates with universities, biotechnology companies and other pharmaceutical groups. Its business model combines proprietary research with licensing, co-development and acquisitions, allowing it to commercialize medicines beyond those discovered entirely in its own laboratories. Servier’s history is also inseparable from the Mediator controversy. Mediator, a benfluorex medicine marketed in France, was withdrawn in 2009 after concerns about serious heart-valve and pulmonary-hypertension risks. The affair led to extensive regulatory, civil and criminal proceedings and became a major French pharmaceutical-safety scandal. French courts later found Servier criminally liable for deception and manslaughter in proceedings concerning the drug, while the company contested aspects of the judicial findings and pursued appeals. The episode prompted scrutiny of pharmacovigilance, regulatory oversight and conflicts involving medicines used outside their principal approved indications. Today Servier presents itself as an independent, international pharmaceutical company with a strong emphasis on innovation and patient access. It remains active in commercial medicines while directing a growing share of strategic attention toward oncology and other specialty-care fields. Precise revenue, employee and market figures are not included here because they vary by reporting period and require a specific dated source.

Servier was established in France in 1954 by Jacques Servier. The company grew as an independent laboratory rather than as a listed multinational, developing and commercializing prescription medicines through a combination of internal research, manufacturing and international licensing. Its early and middle history was associated especially with cardiovascular and general-practice medicines, helping it establish a substantial presence in Europe and other markets. During the late twentieth and early twenty-first centuries, Servier expanded internationally and developed a portfolio that included perindopril-based cardiovascular medicines such as Coversyl, ivabradine under the Procoralan brand, the venous-disease treatment Daflon and medicines in psychiatry and metabolic care. As patents expired and competition increased in established categories, the company sought to renew its pipeline and diversify into higher-specialty fields. A defining negative episode was the history of Mediator, the brand name for benfluorex. The medicine was withdrawn in France in 2009 following safety concerns, particularly associations with valvular heart disease and pulmonary hypertension. Subsequent investigations alleged that the risks had not been adequately communicated and that the product remained available despite concerns raised about its safety profile. The case generated thousands of compensation claims, regulatory criticism and criminal litigation. In 2021, a Paris court convicted Servier of aggravated deception and involuntary manslaughter in the principal criminal proceeding. The litigation and appeals continued to attract public attention, making Mediator one of the most consequential French drug-safety cases. After the Mediator period, Servier emphasized a transformation toward innovation-led specialty pharmaceuticals. Oncology became its principal strategic growth area, supported by alliances, licensing and acquisitions. The company developed a partnership with Taiho Pharmaceutical for Lonsurf, a treatment for advanced colorectal and gastric or gastroesophageal-junction cancers. It acquired the U.S. commercial rights to Onivyde from Merrimack Pharmaceuticals in 2017 and purchased Symphogen in 2019, adding antibody-development expertise. In 2023 Servier completed the acquisition of Agios Pharmaceuticals’ oncology business, broadening its portfolio and pipeline in genetically defined cancers. Servier has also continued research in immuno-inflammation, neuroscience and cardiovascular or metabolic conditions. The group maintains research, manufacturing and commercial operations across a range of countries and works with external academic, biotechnology and pharmaceutical partners. Its independent ownership allows it to pursue long development cycles, although it remains exposed to the same clinical, regulatory, reimbursement and patent risks as other research-based pharmaceutical companies. In the 2020s, Servier’s public identity has increasingly centered on oncology, precision medicine and specialty care. Vorasidenib, marketed in the United States as Voranigo, became a major milestone after U.S. approval in 2024 for certain patients with susceptible IDH-mutant grade 2 gliomas. Alongside newer specialty products, Servier continues to market established medicines through country-specific brands and licensing arrangements. The group remains privately held and led by Olivier Laureau, who became president and chief executive in 2014.

• 2024

  Voranigo receives U.S. approval

  [3]U.S. FDA approval of vorasidenibfda.gov

  The FDA approves vorasidenib for certain patients with IDH-mutant grade 2 astrocytoma or oligodendroglioma.

• 2023

  Agios oncology acquisition closes

  [6]Servier acquisition of Agios oncology businessservier.com

  Servier completes the acquisition of Agios Pharmaceuticals’ oncology business.

• 2019

  Symphogen joins Servier

  [5]Servier acquisition of Symphogenservier.com

  Servier acquires Symphogen to strengthen antibody research and oncology capabilities.

• 2017

  Onivyde rights acquisition

  [7]Onivyde rights acquisitionservier.com

  Servier acquires U.S. rights to the oncology medicine Onivyde from Merrimack Pharmaceuticals.

• 2014

  Olivier Laureau becomes chief executive

  [2]Servier governanceservier.com

  Olivier Laureau succeeds Jacques Servier as president and chief executive after the founder's death.

• 2009

  Mediator is withdrawn in France

  [4]European Medicines Agency Mediator referral assessmentema.europa.eu

  Benfluorex is removed from the French market amid concerns about cardiac-valve disease and pulmonary hypertension.

• 1954

  Servier is founded

  [1]Servier historyservier.com

  Jacques Servier establishes the French pharmaceutical laboratory that becomes Servier.

Independent, research-driven international pharmaceutical group with an increasingly concentrated focus on oncology and specialty medicines.

• Venous disease medicine

  Daflon

  Daflon is Servier’s flavonoid-based venous-disease brand, commonly associated with treatment of symptoms of chronic venous disease and haemorrhoidal disease. Its formulation and approved indications vary by market.

• Cardiovascular medicine

  Coversyl

  Coversyl is a perindopril-based angiotensin-converting enzyme inhibitor brand used in cardiovascular indications such as hypertension and, depending on jurisdiction, related cardiovascular-risk management. It is an established product with generic competition in many markets.

• Cardiovascular medicine

  Procoralan

  Procoralan contains ivabradine and is used in specified cardiovascular conditions, including selected forms of chronic heart failure and chronic stable angina under applicable local labels. It became one of Servier’s best-known specialty cardiovascular products.

• Psychiatric medicine

  Valdoxan

  Valdoxan is the European brand for agomelatine, an antidepressant acting on melatonin receptors and serotonin pathways. Its use is subject to local authorization, prescribing information and liver-function monitoring requirements.

• Oncology medicine

  Lonsurf

  Lonsurf is the Servier-associated brand for trifluridine/tipiracil, an oral antineoplastic treatment developed with Taiho Pharmaceutical. It is used in specified advanced colorectal and gastric or gastroesophageal-junction cancers and is commercialized under country-specific arrangements.

• Oncology medicine

  Onivyde

  Onivyde is a liposomal formulation of irinotecan used in defined treatment settings for metastatic pancreatic cancer, generally in combination regimens. Servier acquired U.S. commercial rights from Merrimack Pharmaceuticals while rights and arrangements differ by territory.

• Precision oncology medicine · 2024

  Voranigo

  Voranigo is the U.S. brand name for vorasidenib, an oral inhibitor targeting mutant IDH1 and IDH2 enzymes. The FDA approved it in 2024 for certain patients with susceptible IDH-mutant grade 2 astrocytoma or oligodendroglioma.

• 2021

  Paris court finds Servier guilty over Mediator and imposes fine

  A Paris court found Servier guilty of manslaughter and deception over the weight-loss drug Mediator and fined the company 2.7 million euros.

  Source

• 2009

  Mediator drug-safety scandal

  Mediator, a benfluorex medicine marketed by Servier, was withdrawn in France after concerns about serious cardiac-valve and pulmonary-hypertension risks. The affair led to regulatory investigations, compensation proceedings and criminal litigation. In 2021 a Paris court convicted Servier of aggravated deception and involuntary manslaughter in the principal criminal case.

  Source

Read more

• 2023

  Acquire Agios oncology businessM&A

  Background

  Servier sought to accelerate its oncology strategy and add genetically targeted cancer medicines.

  Action taken

  Servier completed the acquisition of Agios Pharmaceuticals’ oncology business, including vorasidenib and related assets.

  Aftermath

  The acquisition expanded Servier’s precision-oncology portfolio and supported the later U.S. launch of Voranigo.

  Source

• 2019

  Acquire SymphogenM&A

  Background

  Servier aimed to strengthen biologics and antibody research, particularly for oncology.

  Action taken

  Servier acquired Symphogen, a Danish biotechnology company specializing in antibody therapeutics.

  Aftermath

  Symphogen’s capabilities were incorporated into Servier’s research and development activities.

  Source

• 2017

  Acquire U.S. Onivyde rightsM&A

  Background

  Servier was seeking to build a larger oncology business and increase its presence in specialty medicines.

  Action taken

  The group acquired U.S. commercial rights to Onivyde from Merrimack Pharmaceuticals.

  Aftermath

  The transaction expanded Servier’s U.S. oncology portfolio and commercial infrastructure.

  Source

• 2022.01.18

  Reported2022.01.18

  Servier reports 2020/21 annual results[10]施维雅公布2020/21财年业绩prnewswire.com

  Servier published results for its 2020/21 financial year, reporting consolidated revenue of €4.725 billion, up 4.3% at constant exchange rates.

• 2021.04.14

  Reported2021.04.14

  Servier Ukraine receives Best Place to Work certification[11]Servier Ukraine 获得最佳工作场所认证finanznachrichten.de

  Servier Ukraine was recognized as one of the best places to work in Ukraine for 2021 after an employee survey and HR assessment.

• 2021.03.29

  Reported2021.03.29

  Servier fined over Mediator[9]Paris court finds Servier guilty over Mediator and imposes finebbc.com

  A French court fined drug maker Servier €2.7 million after finding it guilty of aggravated deceit and involuntary manslaughter over the weight-loss drug Mediator. The court said Servier knew of the risks for years and failed to take necessary measures.

• 2021.03.29

  Reported2021.03.29

  Paris court finds Servier guilty over Mediator and imposes fine[8]Paris court finds Servier guilty over Mediator and imposes finenationalpost.com

  A Paris court found Servier guilty of manslaughter and deception over the weight-loss drug Mediator and fined the company 2.7 million euros.

• 2021.03.18

  Reported2021.03.18

  Elsevier releases updated DDIRC 2.0 in PharmaPendium[12]Elsevier在PharmaPendium推出更新版DDIRC 2.0finanznachrichten.de

  Elsevier, together with pharmaceutical collaborators, further refined and extended its drug-drug interaction risk calculator in PharmaPendium. The DDIRC 2.0 release includes updated visualizations and filters, a more comprehensive dataset, and improved dossier submission support.

• 2020.06.04

  Reported2020.06.04

  Servier completes acquisition of Symphogen[13]施维雅完成对Symphogen的收购prnasia.com

  Servier announced that it had completed its acquisition of Symphogen A/S. Symphogen will operate as an antibody center of excellence within Servier and retain operational autonomy, its employees and its headquarters in Ballerup, Denmark.

• Unconfirmed

  Reported2019.10.03

  Servier acquires worldwide rights to Pixuvri[14]施维雅收购 Pixuvri 全球权利pharmatimes.com

  Servier acquired CTI BioPharma’s Pixuvri therapy after the companies completed an Asset Purchase Agreement transferring worldwide rights to Servier.

• 2019.10.01

  Reported2019.10.01

  Servier completes acquisition of PIXUVRI rights[15]Servier完成PIXUVRI权利收购financialpost.com

  Servier announced that it acquired PIXUVRI from CTI BioPharma and that an asset purchase agreement transferred worldwide rights to Servier.

Read more

1. 1Servier historyservier.com
2. 2Servier governanceservier.com
3. 3U.S. FDA approval of vorasidenibfda.gov
4. 4European Medicines Agency Mediator referral assessmentema.europa.eu
5. 5Servier acquisition of Symphogenservier.com
6. 6Servier acquisition of Agios oncology businessservier.com
7. 7Onivyde rights acquisitionservier.com
8. 8Paris court finds Servier guilty over Mediator and imposes finenationalpost.com
9. 9Paris court finds Servier guilty over Mediator and imposes finebbc.com
10. 10施维雅公布2020/21财年业绩prnewswire.com
11. 11Servier Ukraine 获得最佳工作场所认证finanznachrichten.de
12. 12Elsevier在PharmaPendium推出更新版DDIRC 2.0finanznachrichten.de
13. 13施维雅完成对Symphogen的收购prnasia.com
14. 14施维雅收购 Pixuvri 全球权利pharmatimes.com
15. 15Servier完成PIXUVRI权利收购financialpost.com
16. 16Servier acquires lymphoma drug Pixuvri from CTI BioPharmapharmaceutical-business-review.com